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A B S T R A C T
Objective: Alterations in the microbiota composition of the gastro-intestinal
tract are suspected to be involved in the etiopathogenesis of two closely related systemic inﬂammatory autoimmune diseases: primary Sjögren's syndrome (pSS) and
systemic lupus erythematosus (SLE). Our objective was to assess whether alterations in gut and oral microbiota compositions are speciﬁc for pSS and SLE.
Methods: 16S ribosomal RNA gene sequencing was performed on fecal samples from 39 pSS patients, 30 SLE patients and 965 individuals from the general po-
pulation, as well as on buccal swab and oral washing samples from the same pSS and SLE patients. Alpha-diversity, beta-diversity and relative abundance of
individual bacteria were used as outcome measures. Multivariate analyses were performed to test associations between individual bacteria and disease phenotype,
taking age, sex, body-mass index, proton-pump inhibitor use and sequencing-depth into account as possible confounding factors.
Results: Fecal microbiota composition from pSS and SLE patients diﬀered signiﬁcantly from population controls, but not between pSS and SLE. pSS and SLE patients
were characterized by lower bacterial richness, lower Firmicutes/Bacteroidetes ratio and higher relative abundance of Bacteroides species in fecal samples compared
with population controls. Oral microbiota composition diﬀered signiﬁcantly between pSS patients and SLE patients, which could partially be explained by oral
dryness in pSS patients.
Conclusions: pSS and SLE patients share similar alterations in gut microbiota composition, distinguishing patients from individuals in the general population, while
oral microbiota composition shows disease-speciﬁc diﬀerences between pSS and SLE patients.
1. Introduction
Primary Sjögren's syndrome (pSS) and systemic lupus er-
ythematosus (SLE) are systemic inﬂammatory autoimmune diseases
that share epidemiological, clinical, pathogenic and etiological features
[1,2]. The world-wide prevalence rates for pSS and SLE are 0.01–0.09%
and 0.02–0.24%, respectively, with a female:male ratio of 10:1 for both
diseases [3–6]. pSS is characterized by chronic inﬂammation of the
exocrine glands, in particular the salivary and lacrimal glands, resulting
in oral and ocular dryness (sicca) complaints [7,8]. In SLE, a wide range
of symptoms can be present, such as skin rash, photosensitivity, ar-
thritis, glomerulonephritis, pericarditis, neurologic and hematological
symptoms [2]. Overlap of clinical symptoms is frequently observed in
pSS and SLE patients [7,9,10].
Host genetics and environmental factors are important etiological
factors in pSS and SLE. pSS and SLE patients share genetic risk loci
which predisposes individuals to these diseases. Genetic risk loci for
both pSS and SLE include STAT4 and IRF5 (involved in innate im-
munity), IL12A and BLK (involved in adaptive immunity) and HLA class
II region [11–14]. Many more genetic risk factors are currently known
for SLE than for pSS [11]. The majority of SLE genetic risk factors are
involved in innate immune signaling (e.g. TLR7 and TLR9) and lym-
phocyte signaling (e.g. IL-10, CD80) [15].
Despite increasing knowledge on genetic risk factors, still relatively
little is known about environmental factors involved in the develop-
ment of pSS and SLE. In this respect, the microbial composition in the
gut and oral cavity may be important factors in the etiopathogenesis of
these two chronic inﬂammatory autoimmune diseases [16–20]. Several
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recent studies reported diﬀerences in gut and oral microbiota of pSS
and SLE patients compared with healthy- and symptom-controls
[17–19,21–24]. However, it is unknown whether gut and oral micro-
biota of pSS and SLE patients are truly speciﬁc for the disease, as there
are no direct comparative studies including both diseases. Therefore,
the aims of this study were to identify disease-speciﬁc diﬀerences in gut
and oral microbiota of pSS and SLE patients and to assess whether pSS
and SLE patients share overlapping signatures in gut microbiota com-
position. To address these questions, we performed 16S ribosomal RNA
(rRNA) sequencing on fecal, buccal swab and oral washing samples
from 39 pSS patients and 30 SLE patients that passed quality control.
Fecal samples from 965 individuals from the general population, living
in the same geographical area as pSS and SLE patients, were processed
using the same pipeline and were used to assess shared signatures in
pSS and SLE gut microbiota composition.
2. Patients and methods
2.1. Patients
2.1.1. pSS and SLE patients
This study was approved by the Medical Ethical Committee (METc)
of the University Medical Center Groningen (UMCG), Groningen, the
Netherlands (METc 2015.472). All patients completed a written in-
formed consent according to the declaration of Helsinki. Clinically di-
agnosed pSS patients (n= 40) and SLE patients (n=35), living in one
of the northern three provinces of the Netherlands, were consecutively
selected for participation during a standard follow-up consultation at
the UMCG Sjögren's Expertise Center. The UMCG is a tertiary referral
center for Sjögren's syndrome (SS) and SS-associated mucosa associated
lymphoid tissue (MALT) tumors. No selection based on race or ethnic
background was made. Patients who had undergone abdominal surgery
with (partial) bowel resection were not selected for participation.
All pSS patients fulﬁlled the 2016 American College of
Rheumatology/European League Against Rheumatism (ACR/EULAR)
classiﬁcation criteria [25]. All SLE patients fulﬁlled the 2012 Systemic
Lupus International Collaborating Clinics (SLICC) classiﬁcation criteria
[26]. SLE patients using immunosuppressive drugs, other than hydro-
xychloroquine and low dose prednisolone (maximum of 7.5 mg daily),
were excluded. Furthermore, SLE disease activity index (SLEDAI) was
≤4, in order to select disease controls with stable disease and low
disease-activity. Routinely, when there is a clinical suspicion of sec-
ondary SS (e.g. sicca complaints), SLE patients are scheduled for a di-
agnostic workup in the Sjögren's Expertise Center. This workup includes
additional blood serology, functional tests of tear production (Schir-
mer's test, ocular staining score), saliva production (unstimulated whole
saliva) and a salivary gland biopsy. Each patient had to complete the
Dutch Healthy Diet Food Frequency Questionnaire (DHD-FFQ) [27],
the WHO Oral Health Questionnaire for Adults [28], the Xerostomia
Inventory questionnaire [29] and the Rome III Diagnostic Ques-
tionnaire on irritable bowel syndrome (IBS) [30]. Demographic, clin-
ical, biochemical and medication data were retrieved from standardized
electronic medical records. Unstimulated (UWS) and stimulated (SWS)
whole salivary ﬂow rates in mL/min, routinely collected in pSS pa-
tients, were collected. Patients were required not to have used systemic
antibiotics two months before stool and oral sampling.
2.1.2. General population controls
Population controls (n= 974) consisted of individuals participating
in a population cohort study in the northern three provinces of the
Netherlands, LifeLines DEEP [31,32]. In order to represent the general
population as well as possible, population controls were not matched to
pSS or SLE patients. Fecal samples and relevant phenotype data were
available for 974 individuals. Individuals reported to use systemic an-
tibiotics, anti-malarial or anti-fungal therapy were excluded (n=9),
leaving 965 population controls for analyses.
2.2. Methods
2.2.1. Fecal and oral sample collection and DNA isolation
Fecal and oral (i.e., buccal swab and oral washing) samples were
collected from 40 pSS and 35 SLE patients. The required number of
patients to include in this study was based on previous studies on the
gut microbiome in rheumatoid arthritis (RA), pSS and SLE [18,21,33].
Fecal samples from the 965 population controls were previously col-
lected (Lifelines DEEP) [31]. All fecal samples, from patients and po-
pulation controls, were collected at home. pSS and SLE patients col-
lected oral samples in the same week as fecal samples, before breakfast
and oral hygiene activities. Directly after collection, samples were
frozen by participants (i.e., patients and population controls) and stored
in the participants' home freezer. Within two weeks after sampling, a
research assistant visited each participant to collect the fecal and oral
samples. Samples were transported on dry ice to the hospital and stored
at −80 °C. DNA isolation on all fecal samples was performed exactly
the same, using the AllPrep DNA/RNA Mini kit (Qiagen, Venlo, the
Netherlands). DNA isolation on buccal swabs and oral washings was
performed with the Ultraclean Microbial DNA isolation kit (MO BIO,
Carlsbad, California, USA). See Supplementary methods for details.
2.2.2. 16S rRNA gene sequencing, quality control and taxonomy
assignment
Illumina Miseq-v2 paired-end sequencing, covering the V4 variable
region (Primers: 515F [GTGCCAGCMGCCGCGGTAA] and 806R [GGA-
CTACHVGGGTWTCTAAT]), was performed the same on all fecal and
oral samples using standardized sequencing techniques (see
Supplementary Methods). Paired-end read alignment and quality con-
trol on samples from pSS and SLE patients was performed using
Quantitative Insights Into Microbial Ecology (QIIME) v1.9.1 and for
population controls with custom scripts [34], both with a minimum
phred-quality score of 33. Rarefaction was performed at 8000 reads/
sample for fecal samples and 5000 reads/sample for oral samples.
Samples with lower number of reads/sample than these cut-oﬀs were
excluded.
The naïve Bayesian Ribosomal Database Project (RDP) Classiﬁer
was used to assign bacterial 16S rRNA sequences to genus level with
SILVA128 as reference database [35,36]. Scripts on rarefaction and
taxonomy assignment are available on https://github.com/alexa-kur/
miQTL_cookbook. After taxonomy assignment, taxa observed only once
in a sample and taxa with a relative abundance below 0.01% were re-
moved.
Secondly, the ARB software environment (release 5.5) was used to
gain more insight in species distribution [37]. ARB aligns 16S rRNA
reads based on nucleotide sequence and secondary 16S rRNA gene
structure information. To assign 16S rRNA reads to species level, a less
stringent cut-oﬀ for read assignment was applied. Therefore, ARB was
used as secondary taxonomy assignment method solely and not as
primary discovery method.
2.2.3. Statistical analyses
QIIME was used to determine alpha-diversity (i.e., bacterial di-
versity within one sample) and beta-diversity (i.e., diversity in bacterial
composition between samples). Alpha-diversity was determined as
bacterial richness (Chao1) and diversity (Shannon index). Beta-di-
versity was assessed with Bray-Curtis distance matrix and visualized
using principal coordinate analysis (PCoA). Adonis function from the
vegan R-package was used to describe how much of the variation in
Bray-Curtis distance could be explained by each phenotype, using 999
permutations and the R2-value as explanatory estimate.
R (version 3.3.1) was used for comparative statistics [38]. A Ben-
jamini Hochberg false discovery rate (FDR) corrected p-value (q-value)
was calculated for comparative tests. A q-value< 0.05 was used as cut-
oﬀ for comparative statistical tests. Multivariate Association with
Linear Models (MaAsLin, version 0.0.4) was used to ﬁnd bacterial taxa
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Table 1
Characteristics of patients and controls included in gut microbiome analysesa.
pSS SLE Control p-valueb p-valueb
N=39 N=30 N=965 pSS vs SLE pSS, SLE, Control
Age in years, mean ± SD 55 ± 12 47 ± 14 45 ± 13 0.01 < 0.001
Male sex, n (%) 3 [8] 2 [7] 408 [42] 1 < 0.001
White/European ethnic background 36 (92) 28 (93) NA
Born in the Netherlands NA NA 929 (96)
Body-mass index, mean ± SD 25 ± 5 27 ± 5 25 ± 4 0.2 0.2
Smoking, n (%) 4 [10] 9 [30] 194 [20] 0.1 0.1
Disease duration in years, mean ± SD 10 ± 6 11 ± 9 NA 0.6
fulﬁlling ACR EULAR 2016 criteria for SS, n (%) 39 (100) 1 [3] NA
fulﬁlling SLICC 2012 criteria for SLE, n (%) 0 30 (100) NA
Clinically active SLE (%)c NA 6 [20] NA
Serological active SLE (%)c NA 4 [13] NA
Symptoms, ever reported
Arthralgia, n (%) 18 [46] 22 (73) NA 0.03
Raynaud, n (%) 17 [44] 14 [47] NA 0.8
Renal involvement, n (%) 3 [8] 5 [17] NA 0.3
Skin involvement, n (%) 11 [28] 20 [67] NA 0.002
Neuropathy, n (%) 4 [10] 3 [10] NA 1
Oral ulcers, n (%) NA 9 [30] NA
MALT tumor salivary gland, ever diagnosed, n (%) 8 [21] NA NA
Fibromyalgia, n (%) 0 0 23 [2] 0.4
RA, n (%) 0 0 14 [2] 0.6
Diabetes, n (%) 2 [5] 1 [3] NA 1
Serum biochemistry
ANA positive, n (%) 39 (100) 28 (97) NAe 0.4
Anti dsDNA positive, n (%) 1 [4] 15 [50] NA <0.001
ENA positive, n (%) 32 (84) 11 [38] NA <0.001
Ro/SSA positive, n (%) 35 (90) 11 [38] NA <0.001
La/SSB positive, n (%) 21 [54] 5 [17] NA 0.003
Rheumatoid factor positive, n (%) 28 (74) 6 [29] NA 0.007
Lupus Anticoagulant positive, n (%) NA 7 [25] NA
Anti dsDNA at inclusion (IU/mL), mean ± SD NA 15 ± 24 NA
C3 low at inclusion (< 0.90 g/L), n (%) 4 [10] 13 [43] NA 0.002
C4 low at inclusion (< 0.10 g/L), n (%) 4 [10] 3 [10] NA 1
IgG high at inclusion (> 16.0 g/L), n (%) 19 [49] NA NA
Current medication
Proton pump inhibitors, n (%) 13 [33] 18 [60] 68 [7] 0.03 < 0.001
NSAIDS, n (%) 19 [49] 9 [30] 26 [3] 0.1 < 0.001
Corticosteroids, n (%) 2 [5] 5 [17] 2 (0.2) 0.2 < 0.001
Antimalarial, n (%) 0 25 (83) NA <0.001
Rituximab 2 [5] 0 NA
Methotrexate 1 [3] 0 NA
Patient reported disease severity score for SS
ESSPRI Total, mean ± SD 6 ± 2 NA NA
ESSPRI dryness, mean ± SD 6 ± 2 NA NA
ESSPRI fatigue, mean ± SD 6 ± 3 NA NA
ESSPRI pain, mean ± SD 5 ± 3 NA NA
Salivary secretion rate
UWS (mL/min), mean ± SD 0.07 ± 0.11 NA NA
SWS (mL/min), mean ± SD 0.20 ± 0.22 NA NA
Questionnaire resultsd
Irritable Bowel Syndrome, n (%) 17 [46] 6 [23] 165 [22] 0.1 0.004
DHD-FFQ total score, mean ± SD 56 ± 12 52 ± 10 NAf 0.1
DHD ﬁber score, mean ± SD 8 ± 2 7 ± 2 NA 0.03
DHD alcohol score, mean ± SD 9 ± 3 9 ± 2 NA 0.3
a pSS, primary Sjögren's syndrome; SLE, systemic lupus erythematosus; Control, population controls; NA, not available; SD, standard deviation; ACR EULAR,
American College of Rheumatology European League Against Rheumatism; SLICC, Systemic Lupus International Collaborating Clinics; MALT, mucosa-associated
lymphoid tissue; RA, Rheumatoid Arthritis; ANA, antinuclear antibody; dsDNA, double-stranded DNA; ENA, extractable nuclear antigen; Ro/SSA, anti-Ro/Sjögren's
Syndrome autoantibody A; La/SSB, anti-La/Sjögren's syndrome autoantibody B; C3/C4, complement C3/C4; IgG, Immunoglobulin G; NSAIDS, non-steroidal anti-
inﬂammatory drugs; ESSPRI, EULAR Sjögren's syndrome patient reported index; UWS/SWS, unstimulated/stimulated whole salivary ﬂow; DHD, Dutch healthy diet;
FFQ, food frequency questionnaire.
b P-values for pSS and SLE statistical comparisons were calculated with the t-test or Fisher's exact test. P-values for the overall study population were calculated
with the one-way ANOVA or Chi-squared test.
c Clinically and serological SLE activity was clinically determined by the treating physician.
d Questionnaires were returned by 37/39 (95%) of pSS patients and 26/30 (87%) of SLE patients.
e Serum biochemistry was not available for population controls. A previous study showed that serum ANA (titer> 1:160) is positive in 6.1% of the general
population and that anti-Ro/SSA, anti-La/SSB and anti-dsDNA is positive in 0.2–0.8% of the general population [66].
f DHD-FFQ data was not available for population controls.
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associated with pSS and SLE [39]. In MaAsLin, the following factors
were taken into account as possible confounders in the taxa-phenotype
association analyses: age, sex, body-mass index (BMI), smoking, diet
(i.e., DHD-FFQ score, only available for pSS and SLE patients), proton-
pump inhibitor (PPI)-use and sequencing-depth [40,41]. A q-value<
0.10 was used as signiﬁcance cut-oﬀ for taxa-phenotype associations.
3. Results
3.1. Characteristics of the study population
Demographic and clinical characteristics of the study groups are
summarized in Table 1. After quality control, 39 fecal samples from pSS
patients, 30 fecal samples from SLE patients and 965 fecal samples from
population controls were used in the analyses. SLE patients were
slightly younger on average than pSS patients, corresponding to peak
incidence ages for these diseases [3,4]. Eight out of 39 pSS patients
(21%) had developed a mucosa associated lymphoid tissue (MALT)
tumor in the course of the disease. Of the eight pSS patients with a
history of MALT, seven patients either ﬁnished treatment more than
one year before inclusion or were on a wait-and-see policy. Only one
pSS patient with a MALT history received maintenance therapy with
rituximab during the study. The vast majority of clinical characteristics
was similar between pSS patients with and without a history of salivary
gland MALT tumor (Supplementary Table 1). No diﬀerences were ob-
served between pSS patients with and without a MALT tumor in the
disease history, regarding the number of reads per fecal sample and the
alpha- and beta-diversity of the gut microbiome.
Three pSS patients used immunosuppressive drugs during the study,
of which two rituximab and one methotrexate. None of the pSS patients
was treated with antimalarials. This is in accordance with a recent
study showing that antimalarials are not eﬀective in reducing symp-
toms in pSS-patients [42]. Instead, non-steroidal anti-inﬂammatory
drugs (NSAIDs) were prescribed in 49% of pSS-patients, mainly because
of arthralgia symptoms. SLE patients were mainly treated with anti-
malarial therapy (83%). A full history of immunomodulating agents
used by pSS and SLE patients, before inclusion in the study, can be
found in Supplementary Table 2. PPIs were prescribed more often in
SLE-patients (60%) than in pSS patients (33%) and in population con-
trols (7%). To date, no studies are available that show a relation be-
tween antimalarial therapy and changes in the gut or oral microbiome.
However, PPI-use can aﬀect the gut microbiome [41] and was therefore
included as possible confounder in our multivariate statistical model
testing for disease-microbiota associations [39,41].
3.2. Alpha- and beta-diversity of the gut microbiome
Alpha-diversity measures of richness and diversity in fecal samples
did not signiﬁcantly diﬀer between pSS and SLE (q= 0.35 and
q= 0.93, respectively; Fig. 1A). Richness was signiﬁcantly lower in
samples from pSS and SLE patients compared with those from popu-
lation controls (both q=0.0004), but the within-sample diversity did
not diﬀer between pSS, SLE and population controls (both q=0.7).
Principal coordinate analysis (PCoA) of fecal samples from pSS and SLE
patients showed no disease-speciﬁc clustering pattern (Fig. 1B). Disease
phenotype (i.e., presence of pSS or SLE) did not signiﬁcantly contribute
to the variation in fecal bacterial composition between individuals
(adonis, R2= 0.026, p= 0.07). In the PCoA including 965 population
controls disease phenotype (i.e., presence of pSS, SLE or population
control) explained 1.7% of the variation in fecal bacterial composition
between individuals (adonis, q < 0.01; Fig. 1C). Other factors that
were shown to contribute to the variation in fecal bacterial composition
in the total study population were: age (explaining 1.6%, q= 0.01), sex
(explaining 0.7%, q= 0.01), BMI (explaining 0.5%, q=0.01), smoking
(explaining 0.4%, q=0.02), PPI-use (explaining 0.6%, q < 0.01) and
NSAID-use (explaining 0.2%, q= 0.03) as analyzed by adonis. The
overall gut microbiota composition of women from the general popu-
lation was slightly more similar to that of pSS and SLE patients than
that of men from the general population (Supplementary Fig. 1). This
suggests that a small proportion of the diﬀerence in overall gut mi-
crobiota composition between pSS/SLE patients and population con-
trols might be related to the higher percentage of males in the popu-
lation control group (Table 1). In contrast, the gut microbiota
composition of population controls with higher age, was slightly less
similar to that of pSS and SLE patients (Supplementary Fig. 2). This
indicates that the higher average age of pSS patients compared with the
average age of population controls (Table 1) did not contribute to the
observed diﬀerence in overall gut microbiota composition between pSS
patients and population controls.
3.3. Individual gut bacteria associated with pSS and SLE compared to
population controls
3.3.1. Lower Firmicutes/Bacteroidetes ratio in pSS and SLE patients
Proﬁles of the average bacterial composition at phylum and genus
level in fecal samples were more similar between pSS and SLE than
between patients and population controls (Fig. 2A). A lower ratio be-
tween phyla Firmicutes and Bacteroidetes has previously been observed
in SLE patients compared to control subjects [21,22,43]. We also ob-
served a lower Firmicutes/Bacteroidetes ratio in fecal samples from SLE
patients compared to population controls (q < 0.001), but found a
similarly lower Firmicutes/Bacteroides ratio in pSS patients compared
with population controls (q < 0.001; Fig. 2B).
3.3.2. Individual bacterial taxa associated with pSS and SLE
Next, we assessed whether disease phenotype was associated with
individual bacterial taxa (n=152) using MaAsLin. The majority of
genera associated with each disease, was shared between pSS and SLE
patients compared with population controls (Fig. 2C, Supplementary
Tables 3–5). Six genera showed signiﬁcantly higher and twelve lower
relative abundance in both pSS and SLE patients compared with po-
pulation controls (q < 0.10, Fig. 2D). Although pSS and SLE were also
associated with diﬀerent taxa, none of these associations were sig-
niﬁcant when pSS and SLE patients were compared with each other
(q > 0.10, Supplementary Table 6). Thus, diﬀerence in relative
abundance of individual bacteria was much larger between pSS and SLE
compared to population controls than the variation between the two
diseases.
3.3.3. High relative abundance of Bacteroides species is characteristic for
pSS and SLE, but not associated with Ro60/SSA-status
Phylum Bacteroidetes and genus Bacteroides relative abundance
were most evidently higher in pSS and SLE patients compared with
population controls (Fig. 2D). Also, genus Alistipes (belonging to Bac-
teroidetes) and phylum Proteobacteria showed evidently higher re-
lative abundance in pSS and SLE patients compared with population
controls. We subsequently analyzed which Bacteroides species were
responsible for the higher relative abundance of genus Bacteroides in
pSS and SLE patients, using the ARB software package [37]. The re-
lative abundance of Bacteroides vulgatus, Bacteroides uniformis and Bac-
teroides ovatus was signiﬁcantly higher in both pSS and SLE patients
than in population controls (Wilcoxon, p < 0.01, q < 0.05; Fig. 2E;
Supplementary Table 7). Bacteroides thetaiotaomicron (B. theta) was
signiﬁcantly higher in SLE patients, but not in pSS patients compared to
population controls (Wilcoxon, q= 0.03 and q=0.17, respectively).
Recently, cross-reactivity has been suggested between the gut com-
mensal B. theta and the Ro60-protein [43]. However, we did not ob-
serve a diﬀerent relative abundance of B. theta in anti-Ro/SSA-positive
pSS/SLE patients (n= 46) than in anti-Ro/SSA-negative patients
(n= 22) (Supplementary Fig. 3). Neither did we observe associations
between any other bacterial taxa and serum anti-Ro/SSA-autoantibody
presence using the MaAsLin framework (Supplementary Table 8). Also,
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anti-dsDNA and rheumatoid factor (RF) positivity was not associated
with individual bacterial taxa (q > 0.10), but anti-La/SSB-autoanti-
body positivity in pSS/SLE patients was associated with higher relative
abundance of genus Clostridium sensu stricto (q= 0.05) (Supplementary
Tables 9–11). However, this genus showed signiﬁcantly lower relative
abundance in pSS and SLE patients than in population controls
(Fig. 2D), suggesting that higher Clostridium sensu stricto relative
abundance cannot directly be linked to positive anti-La/SSB autoanti-
body status.
3.4. Oral microbiota composition diﬀers between pSS and SLE patients
3.4.1. Signiﬁcant diﬀerences in alpha- and beta-diversity
Study population characteristics of pSS and SLE patients used for
oral microbiota analyses are summarized in Table 2. Buccal swab
samples from 33 pSS patients and 34 SLE patients and oral washings
from 34 pSS patients and 34 SLE patients passed quality control and
were used in statistical analyses. Richness and diversity were sig-
niﬁcantly higher in buccal swabs and oral washings from SLE patients
than in the same samples from pSS patients (q < 0.05, Fig. 3A). The
bacterial composition in buccal swabs, oral washings and merged oral
samples diﬀered signiﬁcantly between pSS and SLE patients (p < 0.01,
adonis; Fig. 3B and C). Disease phenotype explained 7.8–8.8% of the
variation in oral microbiota composition. Other factors signiﬁcantly
contributing to the variation in overall oral microbiota composition
(i.e., in merged oral samples) were: number of own teeth (14.8%,
q= 0.002), self-reported condition of gums (15.8%, q=0.01), Xer-
ostomia Inventory-score (9.8%, q= 0.002) and severity of oral dryness
sensation (11.3%, q=0.049, adonis; Supplementary Fig. 4). These re-
sults indicate that oral dryness contributes more to oral microbiota
composition than disease phenotype, which corresponds with our pre-
vious ﬁndings [23,24]. Smoking was not a factor aﬀecting the overall
oral microbiota composition in pSS and SLE patients (R2= 0.016,
p=0.4, adonis).
3.4.2. No individual taxa associated with disease-phenotype or Ro60/SSA-
status
Proﬁles of the average bacterial composition at phylum and genus
level in buccal swabs and oral washings showed disease speciﬁc pat-
terns (Fig. 3D). However, no individual bacterial taxon in buccal swabs
or oral washings was signiﬁcantly associated with pSS or SLE (MaAsLin,
q > 0.1). When all samples (i.e., one buccal swab and one oral washing
from each patient) were included in the analysis, 36 taxa showed sta-
tistically signiﬁcant diﬀerences in relative abundance (q < 0.10, see
Supplementary Table 12).
Previously, epitope mimicry between the oral species
Capnocytophaga ochracea and the Ro60/SSA protein has been reported
[16]. However, we did not observe a diﬀerence in relative abundance of
genus Capnocytophaga in anti-Ro/SSA-positive patients (pSS and SLE
patients together) compared with anti-Ro/SSA-negative patients
(Supplementary Fig. 5). Neither did we observe associations between
other taxa and anti-Ro/SSA-positive pSS/SLE patients in MaAsLin.
3.5. Connection between oral and gut microbiota
Recent clinical and experimental studies have suggested that
Fig. 1. Signiﬁcantly lower richness and diﬀerent
bacterial composition in fecal samples from pSS
and SLE patients compared with fecal samples
from population controls (Control). Q-values
represent Benjamini-Hochberg false discovery
rate (FDR) corrected p-values. (A) Alpha-di-
versity measures of richness (Chao1) and di-
versity (Shannon index) in fecal samples. (B and
C) PCoA based on Bray-Curtis distance of fecal
bacterial composition in pSS and SLE patients
shows no signiﬁcant diﬀerence (A), but com-
pared to population controls the fecal bacterial
composition diﬀers signiﬁcantly between the
three study groups (C). Squares represent cen-
troids per group and ellipses the 75% conﬁdence
interval of the centroid.
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increased relative abundance of oral bacteria in the gut may induce
intestinal inﬂammation [34,44]. Local intestinal inﬂammation may
subsequently predispose individuals to systemic inﬂammatory dis-
orders, such as pSS and SLE [45,46]. Therefore, we assessed whether
genera observed in oral samples from pSS and SLE patients were more
prevalent and/or abundant in fecal samples from pSS and SLE patients
than in fecal samples from population controls. The cumulative relative
abundance of oral genera did not diﬀer in fecal samples from pSS pa-
tients, SLE patients or population controls (Fig. 4A). Furthermore, none
of the individual oral genera was more prevalent or abundant in fecal
samples from pSS or SLE patients than in samples from population
controls (Fig. 4B and C). However, Actinomyces presence and relative
abundance was signiﬁcantly lower in fecal samples from pSS patients
than in those from population controls (q = 2.2*10−8 and
q = 4.1*10−8, respectively). The relative abundance of Actinomyces
and Lactobacillus in oral samples signiﬁcantly correlated with their re-
lative abundance in fecal samples (q < 0.05, Kendall's rank
correlation, tau=0.35 and tau=0.24, respectively) (Fig. 4D). Also,
fecal Actinomyces relative abundance correlated negatively with oral
Lactobacillus relative abundance (q < 0.05, tau=−0.31). Further-
more, we observed higher Actinomyces relative abundance in both oral
and fecal samples from SLE patients compared to samples from pSS
patients (Fig. 4E). The diﬀerence in Lactobacillus relative abundance
between diseases was signiﬁcant in oral samples, but not in fecal
samples. Together, these results suggest that speciﬁc oral microbiota
can aﬀect the gut microbiota composition.
4. Discussion
Alterations in gut and oral microbiota composition have previously
been suggested as possible environmental factors in the etiology of pSS
and SLE [16–19,21,43]. However, until now, it was unknown whether
the gut and oral microbiome are speciﬁc for pSS and SLE or that these
diseases share common characteristics in microbiota composition. Here
we show that gut microbiota composition of pSS and SLE patients are
very similar to each other but diﬀer signiﬁcantly from individuals in the
general population. In contrast, oral microbiota composition diﬀers
between pSS and SLE patients.
Living-area, ethnic background, sex, age, technical variations, diet
and medication use can inﬂuence the outcome of gut microbiota ana-
lyses [40,47–51]. Furthermore, ethnicity and living-area also inﬂuence
the phenotypic expression of pSS and SLE patients [52–54]. In this
study, we included pSS and SLE patients from the same geographical
area and with a similar ethnic background as population controls. We
showed that the strong female predisposition in pSS and SLE patients
may have explained a small proportion of the diﬀerence in overall gut
microbiota composition between pSS/SLE patients and population
controls. However, the eﬀect of age on the overall gut microbiome
composition in the total study population was smaller and even op-
posed to the age-diﬀerence observed between pSS patients and popu-
lation controls. Methods for fecal sampling, sequencing and taxonomy
assignment were the same for pSS/SLE patients and population con-
trols. Dutch-Healthy-Diet Food Frequency Questionnaire (DHD-FFQ)-
scores were not available for our general population cohort, but another
Dutch population based study (i.e., Nutrition Questionnaires plus study,
including randomly selected individuals from the central part of the
Netherlands, aged 20–70 years, n= 1235) showed very similar DHD-
FFQ scores as in our pSS and SLE patient cohort [27].
None of the patients or population controls received antibiotic
treatment at time of sampling. As expected, medication use diﬀered
between pSS/SLE patients and population controls. Also, the diﬀerence
in use of antimalarials between pSS and SLE is not surprising, since
antimalarial therapy has not been proven eﬀective in pSS, but is a
standard treatment for SLE [42,55]. Chloroquine and hydroxy-
chloroquine have been reported to inhibit intracellular growth of bac-
teria in vitro, but these drugs do not seem to have any antibacterial
activity or eﬀect on extracellular bacterial growth [56,57]. Despite the
diﬀerence in use of antimalarial therapy, no signiﬁcant diﬀerences were
observed in gut microbiota composition between pSS and SLE patients.
This may indicate that antimalarial therapy has no signiﬁcant eﬀect on
the gut microbiota composition. Only three pSS patients received
treatment with immunomodulating agents during the study, of which
two rituximab and one methotrexate. No evidence is available that ri-
tuximab has an eﬀect on the oral or gut microbiome. No signiﬁcant
Fig. 2. Taxonomic diﬀerences in gut microbiota composition between pSS patients, SLE patients and population controls. (A) Proﬁles of the average relative
abundance per group at phylum and genus level. (B) Log 2 Firmicutes/Bacteroidetes ratio was signiﬁcantly lower in pSS and SLE patients compared to population
controls, but similar between diseases (Wilcoxon). (C) Venn diagram of genera signiﬁcantly associated with pSS and SLE compared to population controls using
MaAsLin (q < 0.10). (D) Phyla (p_) and genera (g_) signiﬁcantly associated with both pSS and SLE compared to population controls (MaAsLin, q < 0.10). (E) The
top 12 Bacteroides species with a relative abundance>0.10% observed in fecal samples from patients and population controls. Black asterisks indicate signiﬁcant
results for both pSS and SLE versus Control, red asterisk indicates signiﬁcant for SLE vs Control (Wilcoxon test, p < 0.01 and q < 0.05). (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
Table 2
Characteristics of pSS and SLE patients included in oral microbiome analysesa.
pSS SLE p-valueb
N=34 N=34
Disease duration, mean ± sd 10 ± 7 10 ± 9 1
Age, mean ± sd 54 ± 13 48 ± 14 0.07
Male sex, n (%) 2 [6] 4 [12] 0.7
Smoking, n (%) 3 [9] 9 [27] 0.1
SLE oral ulcers, n (%) NA 9 [27]
UWS mL/min, mean ± sd 0.08 ± 0.11 NA
SWS mL/min, mean ± sd 0.20 ± 0.21 NA
Questionnaire results
Total Xerostomia Inventory score,
mean ± sdc
38 ± 9 23 ± 8 <0.001
Xerostomia Inventory questionnaire: feeling dry mouth <0.001
Always, n (%) 12 [36] 2 [7]
Very often, n (%) 7 [21] 3 [10]
Often, n (%) 11 [33] 9 [29]
Rarely, n (%) 3 [9] 10 [33]
Never, n (%) 0 7 [23]
Dentition/number of own teeth 0.4
Complete, n (%) 18 [55] 21 [66]
10 to 19, n (%) 2 [6] 3 [9]
1 to 9, n (%) 5 [15] 1 [3]
Edentulous, n (%) 8 [24] 7 [22]
Self-reported condition teeth 0.02
Excellent, n (%) 1 [4] 5 [20]
Very good, n (%) 1 [4] 5 [20]
Good, n (%) 10 [39] 11 [44]
Moderate, n (%) 12 [46] 3 [12]
Bad, n (%) 1 [4] 0
Very bad, n (%) 1 [4] 1 [4]
Self-reported condition gums 0.06
Excellent, n (%) 1 [3] 7 [23]
Very good, n (%) 2 [6] 4 [13]
Good, n (%) 17 [52] 11 [36]
Moderate, n (%) 11 [33] 5 [16]
Bad, n (%) 1 [3] 3 [10]
Very bad, n (%) 1 [3] 1 [3]
a pSS, primary Sjögren's syndrome; SLE, systemic lupus erythematosus;
UWS/SWS, unstimulated/stimulated whole salivary secretion rate.
b P-values were calculated using either the Fisher's exact test or t-test.
c Total xerostomia inventory score in a normal (elderly) population is esti-
mated at 20 [67].
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associations were found between gut microbiota and methotrexate use
in a recent study in the British TwinsUK cohort (a nation-wide registry
of volunteer twins, n= 2737, 89% female, mean age 60 ± 12 SD,
mean BMI 26 ± 5 SD) [49]. Regarding the use of NSAIDs, we found
that NSAID use explained 0.2% of the overall gut microbiota compo-
sition in the total study population (i.e., patients and population con-
trols, n= 1034), suggesting that NSAID use has a very small eﬀect on
the overall gut microbiota composition. In both the TwinsUK cohort
(testing for topical NSAID use) [49] as well as in the LifeLines DEEP
cohort (n=1135, 58% female, mean age 45 range 18–81, mean BMI 25
range 17–49, testing for oral NSAID use) [40], no signiﬁcant eﬀect of
NSAIDs on the gut microbiome was observed. Also, oral corticosteroid
use did not signiﬁcantly aﬀect the gut microbiome in these two large
studies [40,49]. Thus, current evidence indicates that the eﬀect of
NSAID and corticosteroid use on the gut microbiome in humans is ab-
sent or very small. In contrast, PPI-use showed a stronger eﬀect on the
gut microbiome in both the LifeLines DEEP and TwinsUK cohort stu-
dies, and explained 0.6% of the overall gut microbiome composition in
our study. PPI use has been associated with an increased relative
abundance of oral microbiota in the gut microbiota composition [41].
Although more pSS and SLE patients used PPIs than population con-
trols, pSS/SLE patients did not have a higher cumulative relative
abundance of oral microbiota in the gut.
Thus, many possible confounding factors were considered in our
study and the most important factors (i.e., sex, age, smoking, BMI, se-
quencing depth, PPI use) were taken into account in the multivariate
statistical framework MaAsLin [39]. Therefore, the results of this study
implicate that the observed diﬀerences in fecal microbiota composition
between pSS/SLE patients and population controls are related to
biological variations rather than geographical, ethnic, sex, age, tech-
nical, dietary or medication diﬀerences.
Lower richness in gut microbiota composition was present in pSS
and SLE patients compared to population controls. Individuals with low
richness in gut microbiota have higher inﬂammatory markers in blood
(i.e., number of leucocytes and high-sensitivity C reactive protein) than
in individuals with high richness [58]. Furthermore, in pSS patients,
elevated levels of fecal calprotectin are observed, which suggests that
(low grade) intestinal inﬂammation may be present in these patients
[45]. Together, these results suggest a connection between lower gut
microbial richness and local and systemic inﬂammation. However, the
sequence of events remains to be further investigated.
A lower Firmicutes/Bacteroidetes ratio has been observed before in
SLE patients, but not in spondyloarthritis or RA patients [33,59,60].
Therefore, our results suggest that low Firmicutes/Bacteroidetes ratio is
shared between two diseases with signiﬁcant overlap in pathogenesis
(viz. pSS and SLE), but not with systemic rheumatic diseases in general.
Bacteroides species are commensal gut bacteria and are well-known
for their glycan degrading ability and short-chain fatty acid production
[61,62]. These metabolic processes are considered beneﬁcial to the host
and for this reason high Bacteroides relative abundance is not directly
associated with dysbiosis of the gut microbiome. However, recently the
species Bacteroides thetaiotaomicron (B. theta) has been reported as a
potential gut pathobiont. Greiling et al. showed that lysates of B. theta
can bind to serum from anti-Ro60-positive patients [43]. Moreover, B
and T cell responses to the Ro60-protein occurred after mono-
colonization of mice with B. theta and this monocolonization lead to
enhanced lupus-like disease [43]. We did not observe an association
between anti-Ro/SSA-positivity in patients and B. theta relative
Fig. 3. Oral microbiota composition diﬀers signiﬁcantly in buccal swabs and oral washings between pSS and SLE patients. (A) Signiﬁcantly lower richness (Chao1)
and diversity (Shannon index) in buccal swab and oral washing samples from pSS patients compared with SLE patients (Wilcoxon, q-value= FDR corrected p-value).
(B) Bray-Curtis based PCoA on buccal swabs and oral washings shows signiﬁcant diﬀerence in composition between pSS and SLE patients. Squares represent centroids
per group and sample type, ellipses correspond with the 75% conﬁdence interval of the centroid. (C) Disease phenotype explains 8.6% of the variation in overall
bacterial composition between pSS and SLE. (D) Proﬁles of the average relative abundance at phylum and genus level per group show disease speciﬁc diﬀerences in
buccal swabs and oral washings.
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Fig. 4. Connection between oral genera observed in fecal samples. (A) Cumulative relative abundance of nine oral genera observed in fecal samples. Each line is one
study subject. Boxplots summarize the cumulative relative abundance per group and correspond with the y-axis (Wilcoxon). (B) Presence of oral genera in fecal
samples. Absence was deﬁned as relative abundance< 0.0125%. Fisher's exact tests were performed on genera with an overall presence>25%. (C) Relative
abundance of oral genera in fecal samples. Blue asterisk indicates q = 4.1*10−8 for pSS vs population control (Wilcoxon). (D) Correlations between genera observed
in oral and fecal samples. Relative abundances of buccal swab and oral washing samples were merged per individual. The color and size of the dots correspond with
the strength of the correlation (Kendall's tau, q < 0.05). (E) Diﬀerences in Actinomyces and Lactobacillus relative abundance in oral and fecal samples from pSS and
SLE patients (Wilcoxon). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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abundance in fecal samples, similar to the results reported by Greiling
et al. [43]. Possibly, the low relative abundance of B. theta in fecal
samples (< 1%) requires larger numbers of anti-Ro60/SSA-positive and
–negative patients to detect a signiﬁcant diﬀerence between these
groups. To overcome this problem, quantitative microbiome proﬁling,
in contrast to relative microbiome proﬁling, should be applied in future
studies assessing the possible connections between B. theta, SLE and
anti-Ro60/SSA autoantibodies [63]. Interestingly, B. theta relative
abundance was signiﬁcantly higher in SLE patients than in population
controls. Thus B. thetamay also be involved in SLE, independent of anti-
Ro60/SSA autoantibody status.
The diﬀerences in oral microbiota composition between pSS and
SLE patients are similar to what we previously observed between pSS
patients and healthy controls, but also show new insights [23,24].
Previously, we did not observe diﬀerences in alpha-diversity between
pSS patients and healthy controls in buccal swabs or oral washings,
which suggests that the alpha-diversity of the oral microbiome in pSS
patients is relatively normal [23,24]. Here we show that SLE is asso-
ciated with a higher alpha-diversity in both buccal swabs and oral
washings than in pSS patients. Higher alpha-diversity of the subgingival
microbiome has previously been associated with periodontitis [64].
Furthermore, periodontitis prevalence is higher in SLE patients than in
controls, while pSS patients do not have a higher risk of periodontitis
[17,65]. Thus, although we did not clinically assess patients for peri-
odontitis, higher alpha-diversity in SLE patients might be explained by
a higher periodontitis prevalence in the SLE group.
In this study we conﬁrm our previous observation that oral dryness
explains more of the variation in oral microbiota composition than
underlying disease [23,24]. Additionally, we show that self-reported
number of own teeth and condition of gums explain large proportions
(15% and 16%, respectively) of overall oral microbiota composition.
This indicates that questionnaires on oral health can provide valuable
information relevant to oral microbiome analyses.
The unique simultaneous sampling of the oral cavity and the gut
allowed us to ﬁnd correlations between oral and gut relative abun-
dances of Actinomyces and Lactobacillus. This indicates that the oral
microbiota composition inﬂuences that of the gut, supporting the idea
that the oral cavity can serve as reservoir for potential pathobionts
involved in intestinal inﬂammation [44]. Bacterial species- and strain-
level identiﬁcation is needed to further assess whether this oral-gut
microbiota connection plays a role in intestinal dysbiosis and in-
ﬂammation.
A limitation of this study is that the results were not replicated in an
independent cohort, but our results conﬁrm previously reported al-
terations in gut microbiota composition in SLE patients compared to
(healthy) controls [21,22]. Furthermore, by including a large popula-
tion control group, instead of healthy controls, we reduced the risk of
introducing selection bias in assessing whether the gut microbiome is
truly associated with a disease-phenotype.
The results of our study provide an important and solid basis for
future studies on the role of the gut and oral microbiome in pSS and
SLE. Elucidating the cause and eﬀect relationship between the gut mi-
crobiome and pSS/SLE should be the main focus of future studies in-
vestigating the etiopathogenesis of pSS and SLE.
5. Conclusion
In conclusion, we show that pSS and SLE patients share a very si-
milar gut microbiota composition that distinguishes patients from a
large group of controls from the general population. The main char-
acteristics of the gut microbiota composition in pSS and SLE patients
are lower bacterial richness, lower Firmicutes/Bacteroidetes ratio and
higher relative abundance of Bacteroides species. In contrast to the gut
microbiota, the oral microbiota composition in pSS and SLE patients is
determined by disease-related changes in the oral environment.
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